Kopran Limited (KOPRAN.NS)
INR 221.0
(2.62%)
INR 221.0
(2.62%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 992.28 Million INR | 31.89% |
| 2022 | 752.38 Million INR | 0.92% |
| 2021 | 745.48 Million INR | 12.44% |
| 2020 | 663.01 Million INR | -24.82% |
| 2019 | 881.85 Million INR | -0.19% |
| 2018 | 883.51 Million INR | 10.09% |
| 2017 | 802.53 Million INR | -7.41% |
| 2016 | 866.72 Million INR | 29.98% |
| 2015 | 666.81 Million INR | 1.98% |
| 2014 | 653.88 Million INR | -43.38% |
| 2013 | 1.15 Billion INR | 22.36% |
| 2012 | 943.85 Million INR | 46.14% |
| 2011 | 645.86 Million INR | -34.02% |
| 2010 | 978.85 Million INR | -10.93% |
| 2009 | 1.09 Billion INR | -4.31% |
| 2008 | 1.14 Billion INR | -17.19% |
| 2007 | 1.38 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 931.67 Million INR | 0.0% |
| 2023 FY | 992.28 Million INR | 31.89% |
| 2023 Q4 | 992.28 Million INR | 0.0% |
| 2022 Q4 | 752.38 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 1.16 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 752.38 Million INR | 0.92% |
| 2021 Q4 | 745.48 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 745.48 Million INR | 12.44% |
| 2021 Q2 | 853.44 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 629.15 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 663.01 Million INR | 0.0% |
| 2020 FY | 663.01 Million INR | -24.82% |
| 2019 Q2 | 873.36 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 881.85 Million INR | -0.19% |
| 2019 Q4 | 881.85 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 883.51 Million INR | 0.0% |
| 2018 FY | 883.51 Million INR | 10.09% |
| 2018 Q2 | 882.11 Million INR | 0.0% |
| 2017 FY | 802.53 Million INR | -7.41% |
| 2017 Q4 | 820.35 Million INR | 0.0% |
| 2017 Q2 | 788.7 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q4 | 866.72 Million INR | 0.0% |
| 2016 FY | 866.72 Million INR | 29.98% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 623.9 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 683.8 Million INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2015 FY | 666.81 Million INR | 1.98% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 666.81 Million INR | 0.0% |
| 2014 FY | 653.88 Million INR | -43.38% |
| 2013 Q4 | 1.15 Billion INR | 0.0% |
| 2013 FY | 1.15 Billion INR | 22.36% |
| 2012 Q4 | 943.85 Million INR | 0.0% |
| 2012 FY | 943.85 Million INR | 46.14% |
| 2012 Q2 | 1.3 Billion INR | 0.0% |
| 2011 FY | 645.86 Million INR | -34.02% |
| 2010 FY | 978.85 Million INR | -10.93% |
| 2009 FY | 1.09 Billion INR | -4.31% |
| 2008 FY | 1.14 Billion INR | -17.19% |
| 2007 FY | 1.38 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott India Limited | 832.3 Million INR | -19.222% |
| Cipla Limited | 5.59 Billion INR | 82.262% |
| Gland Pharma Limited | 3.72 Billion INR | 73.338% |
| GlaxoSmithKline Pharmaceuticals Limited | 186.65 Million INR | -431.629% |
| Marksans Pharma Limited | 2.44 Billion INR | 59.343% |
| NGL Fine-Chem Limited | 324.42 Million INR | -205.861% |
| Pfizer Limited | 945.4 Million INR | -4.959% |
| Sanofi India Limited | 190 Million INR | -422.255% |
| SMS Pharmaceuticals Limited | 2.8 Billion INR | 64.659% |
| TTK Healthcare Limited | 228.1 Million INR | -335.01% |